Consensus AstraZeneca PLC

Equities

AZN

GB0009895292

Real-time Estimate Cboe Europe Other stock markets 06:50:02 2024-04-19 am EDT			5-day change	1st Jan Change
10,824 ^GBX	-0.82%		-2.17%	+2.11%

Apr. 17	AstraZeneca: presents new data at ECCMID	CF
Apr. 17	The market is pinning its hopes on earnings reports

Evolution of the average Target Price on AstraZeneca PLC

Price target over the last 5 years

History of analyst recommendation changes

461918906f92f598764c.s1BIY_R9rA1-bkCQTkcHvRn3Yh2N1hX7G3gWU5Cvys0.njp6AJMMyH0GWnTBfQVi6HWtFC3kkEeiQh4iPPHgmpieOjEhmgWdYghbEQ~fceac42d00d9ae167a3f9148b66bf0d2

Analyst Recommendations on AstraZeneca PLC

ASTRAZENECA : Receives a Buy rating from JP Morgan	Apr. 17	ZD
ANALYST RECOMMENDATIONS : Las Vegas Sands, Regeneron, Kinder Morgan, Rivian, Royal Caribbean...	Apr. 17
ASTRAZENECA : Deutsche Bank returns to 'Hold	Apr. 16	CF
Deutsche Bank Upgrades AstraZeneca to Hold from Sell, Lifts PT	Apr. 16	MT
ASTRAZENECA : Deutsche Bank drops its Sell rating	Apr. 16	ZD
ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca	Apr. 16
RBC raises Admiral; Barclays cuts Phoenix Group	Apr. 16	AN
ASTRAZENECA : Barclays reiterates its Buy rating	Apr. 15	ZD
Fitch Affirms AstraZeneca Rating on Stable Position in Pharmaceutical Sector	Apr. 12	MT
Shareholder Says AstraZeneca CEO 'Massively Underpaid'	Apr. 10	MT
ASTRAZENECA : Gets a Buy rating from Barclays	Apr. 08	ZD
ASTRAZENECA : Gets a Sell rating from UBS	Apr. 05	ZD
ASTRAZENECA : JP Morgan reiterates its Buy rating	Apr. 05	ZD
ASTRAZENECA : JP Morgan keeps its Buy rating	Apr. 04	ZD
ASTRAZENECA : AstraZeneca should not be overlooked for long	Apr. 03
Bernstein Starts AstraZeneca Coverage at Outperform	Apr. 02	MT
Bernstein starts AstraZeneca at 'outperform'	Apr. 02	AN
Advisers Urge Shareholders to Vote Against AstraZeneca CEO's Pay Plan	Apr. 01	MT
ASTRAZENECA : Deutsche Bank reiterates its Sell rating	Mar. 28	ZD
ASTRAZENECA : Gets a Sell rating from UBS	Mar. 25	ZD
B. Riley Downgrades Fusion Pharmaceuticals to Neutral From Buy on Heels of Announced Sale to AstraZeneca, Adjusts PT to $23 From $13	Mar. 20	MT
Fusion Pharmaceuticals Downgraded by RBC to Sector Perform From Outperform, Speculative Risk Removed, Price Target Raised to $21 From $16	Mar. 20	MT
ASTRAZENECA : UBS reaffirms its Sell rating	Mar. 19	ZD
ASTRAZENECA : Deutsche Bank keeps a Sell rating	Mar. 15	ZD
ANALYST RECOMMENDATIONS : Abbvie, Align Technology; Ulta Beauty, United Airlines, Currys...	Mar. 15

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

136 USD

Average target price

162 USD

Spread / Average Target

+19.09%

High Price Target

222.2 USD

Spread / Highest target

+63.32%

Low Price Target

125 USD

Spread / Lowest Target

-8.10%

Consensus detail

Consensus revision (last 18 months)

Analysts covering AstraZeneca PLC

JPMORGAN	James Gordon
Deutsche Bank Securities
DEUTSCHE BANK RESEARCH	Emmanuel Papadakis
BARCLAYS	Emily Field
UBS	Matthew Weston
alphavalue	Abhishek Raval
Bernstein
B. Riley
RBC Capital Markets
Berenberg Bank
BERENBERG	Luisa Hector
JEFFERIES	Peter Welford
DZ Bank
BMO Capital
Stifel Nicolaus
Jefferies & Co.
CREDIT SUISSE	Dominic Lunn
HSBC
Argus
Morgan Stanley
GOLDMAN SACHS	Keyur Parekh
Bank of America Securities/Merrill Lynch
Danske Bank Group
Kepler Capital Markets
Kepler Cheuvreux
DEUTSCHE BANK	Emmanuel Papadakis
SVB Leerink
Bryan, Garnier & Co.
Societe Generale
Liberum Capital
ODDO BHF
BANK OF AMERICA (BOFA)	Sachin Jain

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar